Description

CL2A is a claevable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. Labetuzumab govitecan used this linker[1].-4°C (Powder, sealed storage, away from moisture and light)-Applications-COVID-19-immunoregulation-Formula-C50H79N9O16-Citation–References-[1]Samantha Congreve, et al. Antibody drug conjugates (ADC). Teknisk- naturvetenskaplig fakultet-CASNumber-2616704-22-2-MolecularWeight-1062.21-Compound Purity-98.17-SMILES-O=C(NC1=CC=C(CO)C=C1)[C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN2N=NC(CNC(C3CCC(CN4C(C=CC4=O)=O)CC3)=O)=C2)=O)=O-Research_Area-Cancer; Inflammation/Immunology-Solubility-DMSO : 200 mg/mL (ultrasonic)-Target-ADC Linker-Isoform-Cleavable Linker-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related